More on ABCL

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+10.5% Growth)
- Ratings (8.7 Score)
- Holders

Upcoming Events

- Earnings (11/9/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

AbCellera (NQ:ABCL)
Delayed: 11.82 +0.45 (3.96%)
Prev. Close $11.37  
Open$11.45 
52 Wk High$ 
52 Wk Low$ 
Day High$11.90 
Day Low$11.08 
P/E N/A  
EPS$ 
Volume3,026,749 

Friends, Peers and Foes (?): ABSI, SDGR, JAZZ, VRTX, HYFT (more...)

Oct 22, 2026 04:05 PM AbCellera to Present at Upcoming Investor Conferences in November 2026
Oct 21, 2026 10:00 AM AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
Oct 12, 2026 02:19 AM UBS Starts AbCellera Biologics (ABCL) at Buy
Oct 8, 2026 04:05 PM AbCellera to present Phase 1/2 data on ABCL635 at menopause meeting
Oct 8, 2026 04:05 PM AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Oct 1, 2026 04:05 PM AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Sep 29, 2026 05:29 AM JPMorgan Starts AbCellera Biologics (ABCL) at Overweight, 'feedback bodes well overall'
Sep 24, 2026 04:59 AM Goldman Sachs Resumes AbCellera Biologics (ABCL) at Neutral
Sep 16, 2026 04:05 PM AbCellera to present Phase 2 data on menopause drug at IMS congress
Sep 16, 2026 04:05 PM AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
View All Articles

Entities mentioned with ABCL

View All Entities